

Press release

Lund December 3rd, 2018

EQL Pharma AB (publ)

Org.no. 556713-3425



EQL Pharma – last day of trading in paid subscribed shares (BTA) on December 5th 2018

The rights issue that was carried out during October and November 2018 has now been registered with the Swedish Companies Registration Office (Sw. Bolagsverket). Last day of trading in EQL Pharma BTA (paid subscribed shares) will be on December 5th, 2018 and the stopping date will be on December 7th, 2018. The new issued shares will be available on securities/custody accounts respectively on December 11th, 2018.

After the rights issue, the share capital amounts to SEK 1,307,862.45 distributed on 29,063,610 shares.

Advisors

Västra Hamnen Corporate Finance AB was financial advisor and Setterwalls Advokatbyrå AB was legal advisor to EQL Pharma in connection with the rights issue. Aqurat Fondkommission AB was the issuing agent.

For further information, please contact:

Christer Fåhraeus
CEO EQL Pharma AB (publ)
Phone: +46 (0) 705 – 60 90 00
E-mail: christer.fahraeus@eqlpharma.com
Website: www.eqlpharma.com

This information was provided by the above contact person for publication on December 3rd, 2018.

About EQL Pharma

EQL Pharma is specialized in developing and selling generics, i.e. drugs that are medically equivalent to the original medicines. The company currently markets 10 niche generics in the Swedish and Danish markets. In addition to these, there is a significant pipeline of additional niche generics (generics with little or no competition except for the original) for launch in 2018 and onwards. The business is currently entirely focused on prescription pharmaceuticals in the Nordic region. EQL Pharma is based in Lund, Sweden, employs 8 (7) people and is listed on Spotlight Stock Market. EQL Pharma also conducts extensive development in cooperation with leading contract manufacturers developers and major pharmaceutical companies in, amongst other countries, India and China.